Ascent Group LLC Boosts Position in Eli Lilly and Company $LLY

Ascent Group LLC boosted its position in shares of Eli Lilly and Company (NYSE:LLY) by 3.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 18,401 shares of the company’s stock after acquiring an additional 580 shares during the quarter. Eli Lilly and Company accounts for 0.7% of Ascent Group LLC’s portfolio, making the stock its 29th biggest holding. Ascent Group LLC’s holdings in Eli Lilly and Company were worth $19,776,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Exencial Wealth Advisors LLC increased its position in Eli Lilly and Company by 189.6% during the third quarter. Exencial Wealth Advisors LLC now owns 17,408 shares of the company’s stock valued at $13,283,000 after acquiring an additional 11,396 shares during the last quarter. Rede Wealth LLC purchased a new stake in Eli Lilly and Company in the third quarter worth about $487,000. Central Pacific Bank Trust Division increased its position in Eli Lilly and Company by 25.8% in the third quarter. Central Pacific Bank Trust Division now owns 8,990 shares of the company’s stock worth $6,859,000 after buying an additional 1,843 shares in the last quarter. Cidel Asset Management Inc. increased its position in Eli Lilly and Company by 26.5% in the third quarter. Cidel Asset Management Inc. now owns 26,726 shares of the company’s stock worth $20,392,000 after buying an additional 5,591 shares in the last quarter. Finally, Spire Wealth Management increased its position in Eli Lilly and Company by 2.2% in the fourth quarter. Spire Wealth Management now owns 27,719 shares of the company’s stock worth $29,789,000 after buying an additional 592 shares in the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Trading Up 0.3%

LLY stock opened at $930.08 on Wednesday. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $1,133.95. The company has a debt-to-equity ratio of 1.54, a current ratio of 1.58 and a quick ratio of 1.19. The company has a market capitalization of $878.76 billion, a price-to-earnings ratio of 40.53, a PEG ratio of 1.09 and a beta of 0.51. The business has a 50 day simple moving average of $988.75 and a two-hundred day simple moving average of $973.25.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Wednesday, February 4th. The company reported $7.54 earnings per share for the quarter, topping the consensus estimate of $7.48 by $0.06. Eli Lilly and Company had a return on equity of 102.94% and a net margin of 31.66%.The business had revenue of $19.29 billion during the quarter, compared to the consensus estimate of $17.85 billion. During the same period in the prior year, the company posted $5.32 EPS. The firm’s revenue for the quarter was up 42.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. Research analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have commented on LLY. Argus upped their price target on Eli Lilly and Company from $930.00 to $1,200.00 and gave the stock a “buy” rating in a research report on Monday, February 9th. Rothschild & Co Redburn upped their price target on Eli Lilly and Company from $775.00 to $830.00 and gave the stock a “neutral” rating in a research report on Monday, January 26th. Zacks Research cut Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research report on Friday, January 30th. Truist Financial restated a “buy” rating on shares of Eli Lilly and Company in a research report on Monday, February 23rd. Finally, Daiwa Securities Group upped their price target on Eli Lilly and Company from $1,230.00 to $1,250.00 and gave the stock a “buy” rating in a research report on Wednesday, February 18th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and a consensus target price of $1,222.22.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: FDA approval of Foundayo creates a new high‑value product opportunity that could add billions to sales and validate Lilly’s oral GLP‑1 strategy. Great News for Eli Lilly Stock Investors!
• Positive Sentiment: CEO Dave Ricks says Lilly is ready to scale production of Foundayo, reducing execution risk and supporting faster commercialization. Eli Lilly CEO Says Company Ready to Scale Production
• Positive Sentiment: Lilly will manufacture the GLP‑1 at a new Houston facility, supporting supply and limiting bottlenecks as demand ramps. Lilly’s $6.5B Houston plant will make its new FDA-approved GLP-1
• Positive Sentiment: Brokerage reaction includes modest price‑target increases and renewed analyst attention, reflecting confidence in Foundayo’s sales potential despite valuation questions. Price Target Raised Following FDA Approval
• Neutral Sentiment: Lilly amended its collaboration with AC Immune to advance next‑generation Tau aggregation inhibitors with IND‑enabling studies planned in 2026 — diversification into neurodegeneration could be material longer term but won’t move near‑term revenue. Eli Lilly Extends AC Immune Tau Pact
• Negative Sentiment: Pricing pressure: Novo Nordisk launched a lower‑priced Wegovy HD at about a 40% lower cash price than Lilly’s offering, raising concerns that price competition could blunt Foundayo’s revenue and margins. Novo Nordisk Unveils $399 Wegovy HD
• Negative Sentiment: Market commentary flags a broader GLP‑1 price war and side‑effect/competition concerns that have driven short‑term profit‑taking and tempered the stock’s post‑approval rally. Price War Dampens Lilly Surge After Oral GLP-1 Wins FDA Nod

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.